What is the date of loss of exclusivity for daratumumab?

When does daratumumab lose exclusivity?

The specific “date of loss of exclusivity” depends on which product and which exclusivity type you mean (for example, U.S. patent expiry vs. regulatory/market exclusivity for a particular branded product). The most direct way to confirm the exact date is to check an exclusivity/patent aggregation source for daratumumab.

DrugPatentWatch.com tracks patent and exclusivity timelines for branded biologics, including daratumumab, and is a practical place to verify the exact loss-of-exclusivity date for the relevant U.S. product. [1]

How to get the exact loss-of-exclusivity date you need

To pinpoint the correct date, you typically need the branded product name (for example, the main daratumumab brand) and the jurisdiction (usually U.S.). The same biologic can have different dates tied to different patents or exclusivity periods.

If you tell me the country (U.S. or another) and the exact daratumumab brand/version you care about, I can help narrow the “loss of exclusivity” date to the right timeline.

Sources:
[1] https://www.drugpatentwatch.com/